NCT06386263 - HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

July 7, 2025

Study Completion Date

July 7, 2025

Conditions

Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast CancerHER2-positive Breast Cancer

Interventions

DRUG

Trastuzumab deruxtecan

This is a non-interventional, observational study. Patients who are enrolled by their clinician will receive T-DXd per routine clinical practice through the PSP.

Trial Locations (1)

L6H1A7

Research Site, Oakville